Bright Minds Biosciences (DRUG) Receivables - Other (2020 - 2025)
For the quarter ending Q3 2022, Receivables - Other rose 18.23% year-over-year to $31636.7, compared with a TTM value of $31636.7 through Sep 2022, up 18.23%, and an annual FY2022 reading of $31636.7, up 18.23% over the prior year.
Bright Minds Biosciences (DRUG) has disclosed Receivables - Other for 2 consecutive years, with $31636.7 as the latest value for Q3 2022.
- Receivables - Other reached $31636.7 in Q3 2022 per DRUG's latest filing, up from $26758.9 in the prior quarter.
- Across five years, Receivables - Other topped out at $31636.7 in Q3 2022 and bottomed at $26758.9 in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Bright Minds Biosciences | 464.72 Mn | 405.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 113,645.18 |
| Jun 30, 2025 | 113,645.18 |
| Mar 31, 2025 | 123,994.68 |
| Mar 31, 2025 | 123,994.68 |
| Mar 31, 2024 | 401,891.41 |
| Mar 31, 2024 | 401,891.41 |
| Jun 30, 2023 | 30,716.85 |
| Jun 30, 2023 | 30,716.85 |
| Mar 31, 2023 | 30,520.61 |
| Mar 31, 2023 | 30,520.61 |
| Dec 31, 2022 | 30,397.10 |
| Dec 31, 2022 | 30,397.10 |
| Sep 30, 2022 | 31,636.72 |
| Sep 30, 2022 | 31,636.72 |
| Dec 31, 2021 | -26,722.73 |
| Dec 31, 2021 | -26,722.73 |
| Sep 30, 2021 | 26,758.88 |
| Sep 30, 2021 | 26,758.88 |
| Sep 30, 2020 | 750.42 |
| Sep 30, 2020 | 750.42 |